|
|
|
Despite a rapid proliferation of new genomic and proteomic discovery tools, there has been no measurable increase in lead compounds.
As a result, pharmaceutical companies have become much more selective in purchasing equipment, disposable supplies and other enabling
technologies. Lucrative deals for Sirna, Adnexus and several monoclonal antibody companies are evidence of the desire for new
tools to improve the odds of clinical success.
In an industry constantly seeking more efficient and effective use of scarce development dollars, out sourcing at all stages -
discovery, preclinical development and clinical development - is essential in the evolving business model.
In-depth knowledge of pharmaceutical and biotechnology companies - what they are looking for in new tools, and how they will
make purchase decisions - is necessary to assure that products and programs are properly positioned and effectively promoted.
Health Advances offers clients that in-depth knowledge and deep experience with strategic decision-making:
- Customer segmentation and unmet needs
- Decision makers and purchasing attributes
- Product/service positioning
- Marketing and sales strategies
- M&A and business development support
- Strategy development
- Business model evolution, from tools to products
|
|
 |
|
|
|
|
|
 learn more
about our work with drug discovery platforms and development services.
|
|
|
|
|
 |
|
|
